Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa. (PubMed, Expert Rev Clin Pharmacol) - Mar 3, 2026 - "This review examines the clinical efficacy and tolerability of topical therapies for EB, with a particular focus on approved treatments such as beremagene geperpavec (B-VEC) and Oleogel-S10, as well as emerging agents like allantoin, diacerein, sirolimus, gentamicin, gentian violet and calcipotriol...The continued use of standardized outcome measures will affect the future progress of studies, as well as using real-world data. Whilst a definitive cure is unlikely for EB, evolving topical strategies have strong potential in providing control of the disease's symptoms and ultimately can improve long-term outcomes."
Journal • Review • Dermatology • Pain
|
|
Dedee F Murrell; Sera Sarsam; Sophie Andreou
|